Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of axi-cel as second-line therapy in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma ineligible for autologous stem cell transplantation
2020-001868-28Phase 2Active
- Sponsor
- LYSARC
- Start
- Jul 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in mature B-cell lymphoma, sponsored by LYSARC. Started Jul 2020; status: active.
02
Drugs
axicabtagene ciloleucel
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on 2020-001868-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001868-28.